Carissa Rollins
Known title: SVP, Chief Information OfficerCIK: 0001916557
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends. Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.
Transaction History
| ACH | ▲ Buy | Grant | 28,914 | $0 | 5/15/2025 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 113 | $8K | 4/5/2025 | View on chart |
| ILMN | ▲ Buy | Grant | 7,283 | $0 | 3/5/2025 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 513 | $52K | 2/15/2025 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 412 | $64K | 11/5/2024 | View on chart |
| ACH | ▲ Buy | Grant | 11,154 | $0 | 5/9/2024 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 122 | $16K | 4/5/2024 | View on chart |
| ILMN | ▲ Buy | Grant | 5,569 | $0 | 3/5/2024 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 404 | $46K | 11/5/2023 | View on chart |
| ACH | ▲ Buy | Grant | 9,344 | $0 | 5/12/2023 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 115 | $27K | 4/5/2023 | View on chart |
| ILMN | ▲ Buy | Grant | 5,037 | $0 | 3/1/2023 | View on chart |
| ACH | ▲ Buy | Grant | 4,490 | $0 | 7/12/2022 | View on chart |
| ILMN | ▲ Buy | Grant | 1,375 | $0 | 4/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Accendra Health Receives NYSE Continued Listing Notice
Accendra Health received a notice from the NYSE regarding continued listing standards, with the company stating its intent to cure the deficiency. This regulatory development adds pressure to a stock that is already trading near its 52-week low. Additionally, Bank of America disclosed a 10.8% stake in the company as of September 30.
Accendra Health Receives NYSE Continued Listing Notice. Accendra Health received a notice from the NYSE regarding continued listing standards, with the company stating its intent to cure the deficiency. This regulatory development adds pressure to a stock that is already trading near its 52-week low. Additionally, Bank of America disclosed a 10.8% stake in the company as of September 30.